Advertisement
Singapore markets closed

  • Straits Times Index

    3,176.51
    -11.15 (-0.35%)
     

  • Nikkei

    37,068.35
    -1,011.35 (-2.66%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • Bitcoin USD

    63,688.05
    -1,623.59 (-2.49%)
     

  • CMC Crypto 200

    1,371.97
    +59.35 (+4.52%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • Dow

    37,986.40
    +211.02 (+0.56%)
     

  • Nasdaq

    15,282.01
    -319.49 (-2.05%)
     

  • Gold

    2,406.70
    +8.70 (+0.36%)
     

  • Crude Oil

    83.24
    +0.51 (+0.62%)
     

  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     

  • FTSE Bursa Malaysia

    1,547.57
    +2.81 (+0.18%)
     

  • Jakarta Composite Index

    7,087.32
    -79.50 (-1.11%)
     

  • PSE Index

    6,443.00
    -80.19 (-1.23%)
     

AstraZeneca resolves Faslodex patent litigation in U.S.

Reuters

(Reuters) - British drugmaker AstraZeneca Plc (AZN.L) said on Wednesday it has entered into an agreement with Sandoz, the generic pharmaceuticals division of Novartis AG (NOVN.S), to resolve Faslodex patent litigation in the U.S.

The company said it agreed to resolve the litigation relating to Sandoz's generic fulvestrant product, for which it is seeking FDA approval.

Fulvestrant is a type of hormonal therapy drug used to treat breast cancer.

The U.S. Faslodex patents are due to expire in January 2021, with paediatric exclusivity continuing until July 2021.

(Reporting by Rahul B in Bengaluru; Editing by Sunil Nair)